Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks

Journal of Human Hypertension

Volumn 27, Issue 12, 2013, Pages 721-728

  Kario, K ^a   Saito, I ^b   Kushiro, T ^c   Teramukai, S ^d   Ishikawa, Y ^e   Hiramatsu, K ^e   Kobayashi, F ^e   Shimada, K ^f  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e DAIICHI SANKYO CO   (Japan)

^f Shin Oyama City Hospital   (Japan)

Author keywords

Angiotensin receptor antagonists; Clinic blood pressure; Home blood pressure monitoring; Morning hypertension; Olmesartan medoxomil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEPRESSED BLOOD PRESSURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HOME; HOSPITAL CARE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; OBSERVATIONAL STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; WHITE COAT HYPERTENSION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DIABETES COMPLICATIONS; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TETRAZOLES; TIME FACTORS;

EID: 84887620441     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.68     Document Type: Article

References (37)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
3. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
4. Kario K, Eguchi K, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Circulation 2003; 108: e72-e73.
5. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-743.
6. Kario K, Ishikawa J, Pickering TG, Hoshide S, Eguchi K, Morinari M et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res 2006; 29: 581-587.
7. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971-975.
8. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111: 1777-1783.
9. Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-home study. Hypertension 2010; 55: 1346-1351.
10. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B et al. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342-1349.
11. Hara A, Ohkubo T, Kondo T, Kikuya M, Aono Y, Hanawa S et al. Detection of silent cerebrovascular lesions in individuals with 'masked' and 'white-coat' hypertension by home blood pressure measurement: the Ohasama study. J Hypertens 2009; 27: 1049-1055.
12. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005; 45: 203-208.
13. Ragot S, Genès N, Vaur L, Herpin D. Comparison of three blood pressure measurement methods for the evaluation of two antihypertensive drugs: feasibility, agreement, and reproducibility of blood pressure response. Am J Hypertens 2000; 13: 632-639.
14. Saito I, Kario K, Kushiro T, Teramukai S, Zenimura N, Hiramatsu K et al. Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST study. Hypertens Res 2013; 36: 177-182.
15. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y et al. European society of hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference on home blood pressure monitoring. J Hypertens 2008; 26: 1505-1526.
16. Committee of CKD Initiative, Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Clin Exp Nephrol 2009; 13: 187-256.
17. Kario K, Sato Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K et al. Inhibitory effects of azelnidipine tablets on early-morning hypertension. Drug R D 2013; 13(1): 63-73.
18. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327-1336.
19. Mori H, Yamamoto H, Ukai H, Yuasa S, Nakajima K, Mikawa T et al. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study. Hypertens Res 2012; 36(3): 202-207.
20. Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. Am J Hypertens 2005; 18: 149-151.
21. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
22. Kario K, Hoshide S, Shimizu M, Yano Y, Eguchi K, Ishikawa J et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan morning surge-target organ protection (J-TOP) study. J Hypertens 2010; 28: 1574-1583.
23. Shimada K, Fujita T, Ito S, Naritomi H, Ogihara T, Shimamoto K et al. The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan hypertension evaluation with angiotensin II antagonist losartan therapy (J-HEALTH) study, a prospective nationwide observational study. Hypertens Res 2008; 31: 1903-1911.
24. Obara T, Ohkubo T, Funahashi J, Kikuya M, Asayama K, Metoki H et al. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. J Hypertens 2005; 23: 1653-1660.
25. Bobrie G, Genè s N, Vaur L, Clerson P, Vaisse B, Mallion JM et al. Is 'isolated home' hypertension as opposed to 'isolated office' hypertension a sign of greater cardiovascular risk? Arch Intern Med 2001; 161: 2205-2211.
26. Kawabe H, Saito I, Saruta T. Status of home blood pressure measured in morning and evening: evaluation in normotensives and hypertensives in Japanese urban population. Hypertens Res 2005; 28: 491-498.
27. Obara T, Ohkubo T, Kikuya M, Asayama K, Metoki H, Inoue R et al. Prevalence of masked uncontrolled and treated white-coat hypertension defined according to the average of morning and evening home blood pressure value: from the Japan home versus office measurement evaluation study. Blood Press Monit 2005; 10: 311-316.
28. Saito I, Kushiro T, Ishikawa M, Matsushita Y, Sagawa K, Hiramatsu K et al. Early antihypertensive efficacy of olemsartan medoxomil. J Clin Hypertens (Greenwich) 2008; 10: 930-935.
29. Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhäger WH, Bulpitt CJ et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the systolic hypertension in Europe trial. J Hypertens 2004; 22: 847-857.
30. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L et al. Blood pressure dependent and independent effects on antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051.
31. Kario K. Morning hypertension: A pitfall of current hypertensive management. JMAJ 2005; 48: 234-240.
32. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283-291.
33. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig 2003; 23: 419-430.
34. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41-50.
35. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010; 55: 976-982.
36. Fliser D, Buchholz K, Haller H. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
37. Nasothimiou EG, Tzamouranis D, Rarra V, Roussias LG, Stergiou GS. Diagnostic accuracy of home vs. ambulatory blood pressure monitoring in untreated and treated hypertension. Hypertens Res 2012; 35: 750-755.